Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Positive Safety Data from Sixth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Highlights: 10 subjects in cohort six intravenously dosed with RECCE® 327 at 4,000mg demonstrated good safety and tolerabilityIndependent Safety Committee to review cohort six data – anticipate...
May 23, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg

Highlights: In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mgIndependent Safety Committee approves cohort six dosing at 4,000mg;...
April 13, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Level

Highlights: 36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good safety and tolerability at 1,000mg Independent Safety Committee...
April 12, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives

SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
March 30, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be safe and well-tolerated Independent Safety Committee to review cohort four data – expect...
March 29, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Receives Research and Development (R&D) Incentive Rebate

SYDNEY, Australia, March 29, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
March 08, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE® 327

Highlights: Independent Safety Committee unanimously recommends cohort four (RECCE® 327 at 1,000mg) to commence; a 20-fold increase from cohort one dose (50mg)Cohort four subjects recruited - RECCE®...
February 23, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Final Subjects Dosed in Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Highlights: Final three subjects in cohort three have been intravenously dosed; RECCE® 327 at 500mg indicating to be safe and well toleratedMilestone achieved with 10 total subjects dosed, maximizing...
February 08, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Highlights: Seven subjects in cohort three intravenously dosed; RECCE® 327 at 500mg indicating to be safe and well tolerated Minimum recruited subjects met (7); additional three (3) at this...
January 19, 2022 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Highlights: Seven subjects in cohort two intravenously dosed with RECCE® 327 (R327) at 150mg met all endpoints - indicating R327 is safe and well toleratedIndependent Safety Committee clears third...